Xentuzumab

Research use only, not for human use.

Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours.

Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinanta humanized monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation.

Xentuzumab (0.01-1 mM; 96 h) inhibits IGF type 1 receptor signaling and (0.1 μM; 48 h) AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cell in a dose-dependent manner.Xentuzumab (0.01-1 mM; 5-10 d) losses of antiproliferative activity against PTEN-null LNCaP or PC-3 cells when PTEN knockdown.Xentuzumab (1 μM; 24-72 h) arrests cell cycle at sub-G1 phase and induces apoptosis in VCaP cells. Western Blot Analysis Cell Line:Prostate cancer VCaP cells Concentration:0.1 μM Incubation Time:24 h and 48 h Result:Increased in cleaved caspase 3/7 and PARP.Decreased the level of phosphorylation of FoxO3a (S253)/FoxO1 (T24).Cell Cycle Analysis Cell Line:Prostate cancer VCaP cells Concentration:1 μM Incubation Time:24 h, 48 h, and 72 h Result:Increased in cleaved caspase 3/7 and induces cell apoptosis. Increased the sub-G1 cell population.

Xentuzumab (200 mg/kg i.p., once weekly for 10 weeks) in inhibits tumor growth in LuCaP 96CR patient-derived xenograft model in mice.Animal Model:Fox Chase CB17 severe combined immunodeficiency (SCID; CB17/lcr-Prkdc scid/lcrlcoCrl) male mice with LuCaP 96CR cell (s.c.)Dosage:200 mg/kg Administration:Intraperitoneal injection; once weekly for 10 weeks; sacrificed 6 hours after the last dose Result:Resulted in significant reductions in tumor volume.

——

Cytoskeleton/Cell Adhesion Molecules

Akt

Akt | IGF-1R

——

——

1417158-65-6

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years